Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-21-000667
Filing Date
2021-12-09
Accepted
2021-12-09 14:58:24
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGFOREST BASKETTMOHAMAD H. MAKHZOUMINEA 16 GP, LLCNEA PARTNERS 16, L.P.NEW ENTERPRISE ASSOCIATES 16, L.P.PAUL WALKERPETER W. SONSINISCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES FUND V, LLC - REGULUS THERAPEUTICS -- SCHEDULE 13D/A geo5_18566.htm SC 13D/A 445393
  Complete submission text file 0001072613-21-000667.txt   447323
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Subject) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-87002 | Film No.: 211481718
SIC: 2834 Pharmaceutical Preparations

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities V, LLC (Filed by) CIK: 0001706444 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A